29.09.2022 00:05:00

Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Weiter zum vollständigen Artikel bei "Sanofi-Aventis S.A. "